By the end of the study, 30% of men no longer met the IPSS criteria for moderate to severe LUTS. Abstract: Henry H Woo,1 Declan G Murphy,2,3 Gerard M Testa,4 Jeremy P Grummet,5 Michael Chong,6 Andrew P Stork7 1Sydney Adventist Hospital Clinical School, University of Sydney, Wahroonga, NSW, 2Division of Cancer Surgery, Peter MacCallum Cancer Centre, Melbourne, VIC, 3Australian Prostate Cancer Research Centre, Epworth Healthcare, Richmond, VIC, 4Shire Urology, Miranda, NSW, 5Australian Urology Associates, Malvern, VIC, 6Department of Urology, Repatriation General Hospital, Daw Park, SA, 7Ipsen Pty Ltd, Glen Waverley, VIC, Australia Purpose: Prostate cancer is often comorbidly associated with lower urinary tract symptoms (LUTS), but few studies have assessed the effects of androgen deprivation therapy on LUTS in this patient group.Patients and methods: We conducted a prospective, noninterventional, multicenter, observational study to assess the effectiveness of triptorelin (11.25 mg every 12 weeks) over 48 weeks in men presenting with local stage T3/4 prostate cancer and moderate to severe LUTS (International Prostate Symptom Score >7) in a routine practice setting in Australia.Results: Of the 44 men who enrolled, effectiveness data were available for 39 men.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |